Blog

How Revolution Medicines chased down EQRx’s $1 billion cash prize

Following product shifts, job cuts, a fateful regulatory decision and a precipitous stock crash, EQRx Inc. remained attractive, if for no other reason than its $1 billion dowry.

Read More